Saxenda / Liraglutide
Evidence gap · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Victoza / Liraglutide
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Zynlonta / Loncastuximab tesirine
Evidence gap · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Selzentry / Maraviroc
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Nucala / Mepolizumab
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Apriso / Mesalamine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Canasa / Mesalamine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Delzicol / Mesalamine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lialda / Mesalamine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Pentasa / Mesalamine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Rowasa / Mesalamine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Otrexup / Methotrexate
Dose or interval change · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Rasuvo / Methotrexate
Dose or interval change · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Zaroxolyn / Metolazone
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lysodren / Mitotane
Restriction or avoidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Provigil / Modafinil
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Singulair / Montelukast sodium
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
CellCept / Mycophenolate mofetil
Restriction or avoidance · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Akynzeo / Netupitant/palonosetron or fosnetupitant/palonosetron
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Opdivo / Nivolumab
Pharmacokinetics only · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Opdualag / Nivolumab and relatlimab-rmbw
Pharmacokinetics only · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lybalvi / Olanzapine and samidorphan l-malate
Restriction or avoidance · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
Benicar HCT / Olmesartan medoxomil-hydrochlorothiazide
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Prilosec / Omeprazole magnesium
Pharmacokinetics only · CrCl normalized to 1.73 m2, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tagrisso / Osimertinib
No adjustment within stated limits · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Trileptal / Oxcarbazepine
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Oxycontin / Oxycodone hydrochloride
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Vectibix / Panitumumab
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Protonix / Pantoprazole sodium
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Suflave / PEG 3350 and electrolytes
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Perjeta / Pertuzumab
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Polivy / Polatuzumab vedotin
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Noxafil / Posaconazole
Restriction or avoidance · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Effient / Prasugrel hydrochloride
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Aciphex / Rabeprazole sodium
Pharmacokinetics only · CrCl normalized to 1.73 m2, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Evista / Raloxifene hydrochloride
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Generic names and brands can lead to different formulations. Select the matching route and release type.
Renal tables retain their indication, units and dialysis assumptions. Do not combine doses and intervals from different protocols.
Read source qualifications, monitoring and interactions. A missing dose or absent result does not mean no adjustment.
See all 26 A-Z review statuses and remaining work | Current evidence additions and verification results
1215 product/formulation records and 1125 selected RX summaries are local. These are selected renal summaries, not complete prescribing monographs. Coverage and independent clinical review remain incomplete.
Review coverage details